Safety Study of Ridaforolimus in Patients With Advanced, Refractory or Recurrent Malignancies (MK-8669-001 AM5)(COMPLETED)
Status:
Completed
Trial end date:
2005-10-01
Target enrollment:
Participant gender:
Summary
Phase 1 trial to determine the safety, tolerability and maximum tolerated dose (MTD) of
ridaforolimus in patients with refractory or recurrent malignancies, including myeloma and
lymphoma.